Therapies directed at the basic defect in cystic fibrosis

P. L. Zeitlin

Research output: Contribution to journalArticle

Abstract

There are over 600 unique mutations in the cystic fibrosis (CF) gene that can be classified in five general categories with respect to specific defect. Through basic research into the genetic and physiologic consequences of these mutations, it has become possible to design genotype-specific therapeutic strategies. New pharmaceutical agents are under development for the rescue of defective cystic fibrosis transmembrane conductance regulator mRNA or protein. Some of these compounds are undergoing study in CF patients in Phase I clinical trials. This article evaluates the current research directed at translating a basic molecular understanding of the disease into innovative new treatments.

Original languageEnglish (US)
Pages (from-to)515-525
Number of pages11
JournalClinics in Chest Medicine
Volume19
Issue number3
DOIs
StatePublished - Jan 1 1998

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Fingerprint Dive into the research topics of 'Therapies directed at the basic defect in cystic fibrosis'. Together they form a unique fingerprint.

  • Cite this